EQS-Adhoc: Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy
|
EQS-Ad-hoc: Bayer Aktiengesellschaft / Key word(s): Study results
Leverkusen/Berlin, November 19, 2023 – OCEANIC-AF, a phase III study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk for stroke is being stopped early. This decision is based on the recommendation of the study’s Independent Data Monitoring Committee (IDMC) as part of ongoing surveillance which showed an inferior efficacy of asundexian versus the control arm. Bayer will further analyze the data to understand the outcome and publish the data.
Available safety data are consistent with previously reported safety profiles of asundexian. The IDMC recommends continuing the OCEANIC-STROKE phase III study as planned. Appropriate measures will be taken to close the OCEANIC-AF study and patients will be contacted by their treating physicians/investigators to discuss next steps. Asundexian is an investigational agent and has not been approved by any health authority for use in any country, for any indication. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Contact: Mr. Peter Dahlhoff, Bayer AG, Investor Relations, Tel.: +49 214 60001494 , e-mail: peter.dahlhoff@bayer.com End of Inside Information Information and Explanation of the Issuer to this announcement: About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com. Contact for investor inquiries: Bayer Investor Relations Team, phone +49 214 30-72704 Email: ir@bayer.com www.bayer.com/en/investors/ir-team
19-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Bayer Aktiengesellschaft |
| Kaiser-Wilhelm-Allee 1 | |
| 51373 Leverkusen | |
| Germany | |
| Phone: | +49 (0)214 30-72704 |
| E-mail: | ir@bayer.com |
| Internet: | www.bayer.com |
| ISIN: | DE000BAY0017 |
| WKN: | BAY001 |
| Indices: | DAX, EURO STOXX 50, Stoxx 50 |
| Listed: | Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart; Regulated Unofficial Market in Tradegate Exchange |
| EQS News ID: | 1776651 |
| End of Announcement | EQS News Service |
|
|
1776651 19-Nov-2023 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 39.586,00 | 43.545,00 | 41.400,00 | 44.081,00 | 50.739,00 | 47.637,00 | 46.000,00 | |
| EBITDA1,2 | 9.695,00 | 9.554,00 | -2.910,00 | 6.409,00 | 13.515,00 | 10.632,00 | 10.000,00 | |
| EBITDA-Margin3 | 24,49 | 21,94 | -7,03 | 14,54 | 26,64 | 22,32 | 21,74 | |
| EBIT1,4 | 3.454,00 | 4.189,00 | -16.169,00 | 3.353,00 | 7.012,00 | 6.460,00 | 5.100,00 | |
| EBIT-Margin5 | 8,73 | 9,62 | -39,06 | 7,61 | 13,82 | 13,56 | 11,09 | |
| Net Profit (Loss)1 | 1.711,00 | 4.110,00 | -10.487,00 | 1.022,00 | 4.166,00 | -2.942,00 | 2.800,00 | |
| Net-Margin6 | 4,32 | 9,44 | -25,33 | 2,32 | 8,21 | -6,18 | 6,09 | |
| Cashflow1,7 | 7.917,00 | 8.207,00 | 4.903,00 | 5.089,00 | 7.093,00 | 5.117,00 | 0,00 | |
| Earnings per share8 | 1,80 | 4,17 | -10,68 | 1,02 | 4,22 | -2,99 | -3,40 | |
| Dividend per share8 | 2,80 | 2,80 | 2,00 | 2,00 | 2,40 | 0,11 | 0,11 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Bayer | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| BAY001 | DE000BAY0017 | AG | 18.603,18 Mio € | 01.05.1948 | Verkaufen | 9F382X7M+F6 |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 11,14 | 23,22 | 0,48 | 9,66 | 0,57 | 3,64 | 0,39 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 2,40 | 0,11 | 0,11 | 0,58% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 25.04.2025 | 13.05.2025 | 06.08.2024 | 12.11.2024 | 05.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -18,57% | -27,54% | -43,69% | -42,10% | +0,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
